CL2013000002A1 - Compuesto derivado de pirazol sustituido; y su uso para tratar enfermedades o condiciones mediadas por el/los receptores pd1, fp, ep1, tp y/o ep4 entregando una respuesta inflamatoria genral, tal com artritis reumatoide, psoriasis, dermatitis atopica, endometrosis, alergia, asma, entre otras. - Google Patents
Compuesto derivado de pirazol sustituido; y su uso para tratar enfermedades o condiciones mediadas por el/los receptores pd1, fp, ep1, tp y/o ep4 entregando una respuesta inflamatoria genral, tal com artritis reumatoide, psoriasis, dermatitis atopica, endometrosis, alergia, asma, entre otras.Info
- Publication number
- CL2013000002A1 CL2013000002A1 CL2013000002A CL2013000002A CL2013000002A1 CL 2013000002 A1 CL2013000002 A1 CL 2013000002A1 CL 2013000002 A CL2013000002 A CL 2013000002A CL 2013000002 A CL2013000002 A CL 2013000002A CL 2013000002 A1 CL2013000002 A1 CL 2013000002A1
- Authority
- CL
- Chile
- Prior art keywords
- receptors
- delivering
- inflammatory response
- endometrosis
- allergy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000028709 inflammatory response Effects 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title 1
- 206010012438 Dermatitis atopic Diseases 0.000 title 1
- 206010020751 Hypersensitivity Diseases 0.000 title 1
- 201000004681 Psoriasis Diseases 0.000 title 1
- 208000026935 allergic disease Diseases 0.000 title 1
- 230000007815 allergy Effects 0.000 title 1
- 208000006673 asthma Diseases 0.000 title 1
- 201000008937 atopic dermatitis Diseases 0.000 title 1
- 206010039073 rheumatoid arthritis Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 108050008995 Prostaglandin F receptors Proteins 0.000 abstract 1
- 101150058615 Ptger1 gene Proteins 0.000 abstract 1
- 101150109738 Ptger4 gene Proteins 0.000 abstract 1
- 108090000300 Thromboxane Receptors Proteins 0.000 abstract 1
- 108090001097 Transcription Factor DP1 Proteins 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36075510P | 2010-07-01 | 2010-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000002A1 true CL2013000002A1 (es) | 2013-05-31 |
Family
ID=44514984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000002A CL2013000002A1 (es) | 2010-07-01 | 2013-01-02 | Compuesto derivado de pirazol sustituido; y su uso para tratar enfermedades o condiciones mediadas por el/los receptores pd1, fp, ep1, tp y/o ep4 entregando una respuesta inflamatoria genral, tal com artritis reumatoide, psoriasis, dermatitis atopica, endometrosis, alergia, asma, entre otras. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8492424B2 (enExample) |
| EP (1) | EP2588459B1 (enExample) |
| JP (1) | JP5922116B2 (enExample) |
| KR (1) | KR20130141434A (enExample) |
| CN (1) | CN103038219B (enExample) |
| AR (1) | AR082073A1 (enExample) |
| AU (1) | AU2011272716B2 (enExample) |
| BR (1) | BR112013000065A2 (enExample) |
| CA (1) | CA2804194C (enExample) |
| CL (1) | CL2013000002A1 (enExample) |
| CO (1) | CO6680625A2 (enExample) |
| ES (1) | ES2625355T3 (enExample) |
| MX (1) | MX2013000170A (enExample) |
| PH (1) | PH12013500121A1 (enExample) |
| RU (1) | RU2013102967A (enExample) |
| SG (1) | SG186886A1 (enExample) |
| TW (1) | TW201206891A (enExample) |
| WO (1) | WO2012003414A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US8859606B2 (en) | 2010-07-01 | 2014-10-14 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
| US9006450B2 (en) | 2010-07-01 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| WO2013096501A1 (en) * | 2011-12-21 | 2013-06-27 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| CA2862266C (en) * | 2011-12-27 | 2016-10-04 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| WO2013101598A1 (en) * | 2011-12-27 | 2013-07-04 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| EP2885008B1 (en) | 2012-08-15 | 2018-11-07 | University Of Virginia Patent Foundation | Compositions and methods for treating peripheral arterial disease |
| WO2014113814A1 (en) * | 2013-01-21 | 2014-07-24 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
| JP2016535048A (ja) * | 2013-10-31 | 2016-11-10 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 結晶形３−｛１−［５−クロロ−２−（２−エチルブトキシ）ベンジル］−５−メチル−１ｈ−ピラゾール−３−イル｝プロパン酸及びその使用方法 |
| CN106146400A (zh) * | 2015-03-20 | 2016-11-23 | 四川大学 | 苄基-1h-吡唑、苄基-1h-吡咯衍生物及其制备方法和用途 |
| US10462745B2 (en) | 2016-01-15 | 2019-10-29 | Google Llc | Systems and methods for extending battery life by monitoring device activity |
| CN107723304A (zh) * | 2016-08-10 | 2018-02-23 | 中国科学院上海生命科学研究院 | Prkar2a在炎症消退中的应用 |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4826868A (en) * | 1986-05-29 | 1989-05-02 | Ortho Pharmaceutical Corporation | 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use |
| US7217725B2 (en) | 2000-09-14 | 2007-05-15 | Allergan, Inc. | Prostaglandin D2 antagonist |
| US6511999B2 (en) | 2000-09-14 | 2003-01-28 | Allergan, Inc. | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists |
| US7273883B2 (en) | 2000-09-14 | 2007-09-25 | Allergan, Inc. | Prostaglandin EP4 antagonist |
| JP2006528938A (ja) * | 2003-05-20 | 2006-12-28 | メルク フロスト カナダ リミテツド | フルオロ−メタンスルホニル置換シクロアルカノインドール、およびプロスタグランジンｄ２アンタゴニストとしてのこれらの使用 |
| EP1675832B1 (en) * | 2003-10-24 | 2008-02-20 | Glaxo Group Limited | Heterocyclyl compounds |
| GB0508472D0 (en) * | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
-
2011
- 2011-06-28 US US13/170,467 patent/US8492424B2/en active Active
- 2011-07-01 WO PCT/US2011/042729 patent/WO2012003414A1/en not_active Ceased
- 2011-07-01 RU RU2013102967/04A patent/RU2013102967A/ru not_active Application Discontinuation
- 2011-07-01 AR ARP110102369A patent/AR082073A1/es unknown
- 2011-07-01 CN CN201180038338.0A patent/CN103038219B/zh not_active Expired - Fee Related
- 2011-07-01 EP EP11734222.0A patent/EP2588459B1/en active Active
- 2011-07-01 TW TW100123408A patent/TW201206891A/zh unknown
- 2011-07-01 MX MX2013000170A patent/MX2013000170A/es active IP Right Grant
- 2011-07-01 ES ES11734222.0T patent/ES2625355T3/es active Active
- 2011-07-01 JP JP2013518748A patent/JP5922116B2/ja not_active Expired - Fee Related
- 2011-07-01 SG SG2013000054A patent/SG186886A1/en unknown
- 2011-07-01 PH PH1/2013/500121A patent/PH12013500121A1/en unknown
- 2011-07-01 BR BR112013000065A patent/BR112013000065A2/pt not_active IP Right Cessation
- 2011-07-01 AU AU2011272716A patent/AU2011272716B2/en not_active Ceased
- 2011-07-01 US US13/808,020 patent/US20140121258A1/en not_active Abandoned
- 2011-07-01 KR KR1020137002639A patent/KR20130141434A/ko not_active Withdrawn
- 2011-07-01 CA CA2804194A patent/CA2804194C/en active Active
-
2013
- 2013-01-02 CL CL2013000002A patent/CL2013000002A1/es unknown
- 2013-01-29 CO CO13016511A patent/CO6680625A2/es unknown
- 2013-05-20 US US13/898,254 patent/US20130253028A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2625355T3 (es) | 2017-07-19 |
| US20140121258A1 (en) | 2014-05-01 |
| US8492424B2 (en) | 2013-07-23 |
| AR082073A1 (es) | 2012-11-07 |
| CN103038219B (zh) | 2016-08-24 |
| US20130253028A1 (en) | 2013-09-26 |
| PH12013500121A1 (en) | 2013-03-11 |
| RU2013102967A (ru) | 2014-08-10 |
| TW201206891A (en) | 2012-02-16 |
| MX2013000170A (es) | 2013-05-28 |
| KR20130141434A (ko) | 2013-12-26 |
| SG186886A1 (en) | 2013-02-28 |
| WO2012003414A1 (en) | 2012-01-05 |
| CO6680625A2 (es) | 2013-05-31 |
| AU2011272716B2 (en) | 2016-05-19 |
| JP2013535424A (ja) | 2013-09-12 |
| BR112013000065A2 (pt) | 2019-09-24 |
| EP2588459A1 (en) | 2013-05-08 |
| CA2804194A1 (en) | 2012-01-05 |
| CA2804194C (en) | 2019-03-05 |
| EP2588459B1 (en) | 2017-03-01 |
| US20120165382A1 (en) | 2012-06-28 |
| CN103038219A (zh) | 2013-04-10 |
| JP5922116B2 (ja) | 2016-05-24 |
| AU2011272716A1 (en) | 2013-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086042A1 (es) | Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica | |
| CO7141404A2 (es) | Procesos para producir ciertos 2 (piridin 3 il)tiazoles | |
| CO7141403A2 (es) | Procesos para producir ciertos 2 (piridin 3 il)tiazoles | |
| IN2012DE00888A (enExample) | ||
| SMT201600174B (it) | Forme solide di acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]diossol-5-il)ciclopropancarbossammido)-3-metilpiridin-2-il)benzoico | |
| MX394473B (es) | Composiciones farmaceuticas que comprenden glitazonas y activadores de nrf2. | |
| UY34092A (es) | Nuevos compuestos como inhibidores de jak | |
| PH12014501066A1 (en) | Self-adhesive lavatory treatment compositions | |
| UY33930A (es) | Inhibidores novedosos de quinasas | |
| CO6852097A2 (es) | Agentes de coalescencia amigables con el medio ambiente | |
| UA113620C2 (xx) | Композиція, що містить аморфну (5-фтор-2-метил-3-хінолін-2-ілметиліндол-1-іл)оцтову кислоту | |
| UA111827C2 (uk) | Спосіб отримання інгенол-3-ангелату | |
| CO6970617A2 (es) | Composición herbicida que contiene ciertos ácidos piridina carboxílicos y el ácido (2,4-diclorofenoxi) acético | |
| CO7141402A2 (es) | Procesos para producir ciertos 2 (piridin 3 il)tiazoles | |
| CL2015002509A1 (es) | Composiciones de control de la corrosión y métodos para mitigar la corrosión. | |
| EA201291235A1 (ru) | Новые способы | |
| IN2015DN02668A (enExample) | ||
| PE20150370A1 (es) | Composiciones herbicidas que comprenden acido 4-amino-3-cloro-5-fluoro-6-(4-cloro-2-fluoro-3-metoxifenilo) piridina-2-carboxilico o un derivado del mismo y un sulfonilaminocarboniltriazolinona | |
| CL2011000093A1 (es) | Compuestos derivados de un ester piperidinilico del acido bifenil-2-ilcarbamico; composicion farmaceutica; combinacion farmaceutica; y su uso para broncoconstriccion, enfermedades obstructivas o inflamatorias de las vias respiratorias. | |
| UY33893A (es) | Nuevo procedimiento de síntesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable | |
| CU20190098A7 (es) | Compuesto derivado de carboxamida útil para inducir la condrogénesis | |
| UY32500A (es) | Nuevo procedimiento de síntesis de la ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable | |
| CR20110589A (es) | Compuestos y métodos para controlar hongos | |
| GB2523674A (en) | Compounds as inhibitor of DNA double-strand break repair, methods and applications thereof | |
| HUE036037T2 (hu) | (3S,3S')4,4'-Diszulfándiil-bisz(3-aminobután-1-szulfonsav), azaz ABSD, L-lizinnel képezett kristályos alakja |